Lutz Jermutus
Overview
Explore the profile of Lutz Jermutus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1564
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papworth M, Kulkarni S, Antonsson M, Sermadiras I, Hovdal D, Connolly K, et al.
Cardiovasc Res
. 2025 Mar;
PMID: 40037346
Aim: Relaxin-2, a well-known human hormone primarily associated with pregnancy, has shown promising cardiovascular benefits in both preclinical models and clinical trials. However, its therapeutic potential has been limited due...
2.
Daniels S, Nelander K, Eriksson J, Jermutus L, Saillard J, Oyesola S, et al.
Contemp Clin Trials Commun
. 2025 Feb;
44:101437.
PMID: 39916681
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease that is heterogenous in nature with various drivers and modifiers such as metabolic dysfunction and genetic factors. MASLD...
3.
Yang B, Devalla D, Sonzini S, Boberg M, Gopaul S, Sundqvist M, et al.
J Control Release
. 2025 Jan;
380:647-663.
PMID: 39875074
Cotadutide (Cota) is a lipidated dual GLP-1 and Glucagon receptor agonist that was investigated for the treatment of various metabolic diseases, it is designed for once daily subcutaneous (SC) administration....
4.
Valdecantos M, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, et al.
Nat Commun
. 2024 Nov;
15(1):10342.
PMID: 39609390
Bariatric surgery is effective for the treatment and remission of obesity and type 2 diabetes, but pharmacological approaches which exert similar metabolic adaptations are needed to avoid post-surgical complications. Here...
5.
Selvarajah V, Robertson D, Hansen L, Jermutus L, Smith K, Coggi A, et al.
Kidney Int
. 2024 Sep;
106(6):1170-1180.
PMID: 39218393
Cotadutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist that may improve kidney function in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). In this phase...
6.
Shankar S, Daniels S, Robertson D, Sarv J, Sanchez J, Carter D, et al.
Clin Gastroenterol Hepatol
. 2024 May;
22(9):1847-1857.e11.
PMID: 38729399
Background & Aims: Cotadutide, a peptide co-agonist at the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, has demonstrated robust improvements in body weight, glycemia, and hepatic fat fraction (HFF) in...
7.
Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, et al.
Diabetes Obes Metab
. 2024 Apr;
26(7):2634-2644.
PMID: 38562018
Aims: To establish which components of energy balance mediate the clinically significant weight loss demonstrated with use of cotadutide, a glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, in early-phase studies. Materials...
8.
Parker V, Robertson D, Erazo-Tapia E, Havekes B, Phielix E, de Ligt M, et al.
Nat Metab
. 2023 Dec;
5(12):2086-2093.
PMID: 38066113
Cotadutide is a dual glucagon-like peptide 1 and glucagon receptor agonist under development for the treatment of non-alcoholic steatohepatitis and type 2 diabetes mellitus (T2DM) and chronic kidney disease. Non-alcoholic...
9.
Lindsay R, Ambery P, Jermutus L, Murray A
Physiol Rep
. 2023 Mar;
11(6):e15597.
PMID: 36946315
The inotropic effects of glucagon have been recognized for many years, but it has remained unclear whether glucagon signaling is beneficial to cardiac function. We evaluated the effects of glucagon...
10.
Zinn S, Vazquez-Lombardi R, Zimmermann C, Sapra P, Jermutus L, Christ D
Nat Cancer
. 2023 Feb;
4(2):165-180.
PMID: 36806801
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high affinity and immune effector functions. In this review, we outline key advances...